KIMBERLY PIENING: Open Payments
NPI 1669734794 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$279 in 15 payments from 8 companies in 2025. Trend: 2023 $186 · 2024 $475 · 2025 $279
Food & beverage: $279
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $81 |
| ABBVIE INC. | 4 | $81 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
Products named: Wegovy, AIRSUPRA, VRAYLAR, UBRELVY, OPSUMIT, QULIPTA, ELIQUIS, Kerendia.
Industry payments across NE — which companies pay providers there.
